Targeting PI3KC2β impairs proliferation and survival in acute leukemia, braintumours and neuroendocrine tumours

Anticancer Research

Volumn 32, Issue 8, 2012, Pages 3015-3027

  Boller, Danielle ^a   Doepfner, Kathrin T ^a   De Laurentiis, Angela ^a   Guerreiro, Ana S ^a   Marinov, Marin ^a   Shalaby, Tarek ^a   Depledge, Paul ^b   Robson, Anthony ^b   Saghir, Nahid ^b   Hayakawa, Masahiko ^c   Kaizawa, Hiroyuki ^c   Koizumi, Tomonobu ^c   Ohishi, Takahide ^c   Fattet, Sarah ^d   Delattre, Olivier ^d   Schweri Olac, Anelia ^e   Höland, Katrin ^e   Grotzer, Michael A ^a   Frei, Karl ^f   Spertini, Olivier ^g   Waterfield, Michael D ^b,h   Arcaro, Alexandre ^a,e   more..

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b Piramed   (United Kingdom)

^c ASTELLAS PHARMA INC   (Japan)

^d INSERM   (France)

^e UNIVERSITY OF BERN   (Switzerland)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h LUDWIG INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

Acute leukemia; Brain tumours; Cell proliferation; Migration; Neuroendocrine tumours; Pharmacological inhibition; PI3KC2

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE C2BETA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; DRUG TARGETING; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG SMALL CELL CANCER; MEDULLOBLASTOMA; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; ISOENZYMES; LEUKEMIA, MYELOID, ACUTE; MICE; NEUROENDOCRINE TUMORS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHATIDYLINOSITOL 3-KINASES; SURVIVAL RATE;

EID: 84865679788     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J and Waterfield MD: Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17: 615-675, 2001. (Pubitemid 33096187)
2. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, Woscholski R, Parker PJ and Waterfield MD: Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 70: 535-602, 2001. (Pubitemid 32662219)
3. Vanhaesebroeck B, Stephens L and Hawkins P: PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol 13: 195-203, 2012.
4. Vanhaesebroeck B, Leevers SJ, Panayotou G and Waterfield MD: Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci 22: 267-272, 1997. (Pubitemid 27310948)
5. Vanhaesebroeck B, Ali K, Bilancio A, Geering B and Foukas LC: Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci 30: 194-204, 2005. (Pubitemid 40463309)
6. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M and Bilanges B: The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 11: 329-341, 2010.
7. Blajecka K, Borgstrom A and Arcaro A: Phosphatidylinositol 3- kinase isoforms as novel drug targets. Curr Drug Targets 12: 1056-1081, 2011.
8. Hiles ID, Otsu M, Volinia S, Fry MJ, Gout I, Dhand R, Panayotou G, Ruiz-Larrea F, Thompson A, Totty NF et al: Phosphatidylinositol 3-kinase: structure and expression of the 110 kDa catalytic subunit. Cell 70: 419-429, 1992.
9. Hu P, Mondino A, Skolnik EY and Schlessinger J: Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85. Mol Cell Biol 13: 7677-7688, 1993. (Pubitemid 23354292)
10. Vanhaesebroeck B, Welham MJ, Kotani K, Stein R, Warne PH, Zvelebil MJ, Higashi K, Volinia S, Downward J and Waterfield MD: P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci USA 94: 4330-4335, 1997. (Pubitemid 27194241)
11. Chantry D, Vojtek A, Kashishian A, Holtzman DA, Wood C, Gray PW, Cooper JA and Hoekstra MF: p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem 272: 19236-19241, 1997. (Pubitemid 27337713)
12. Otsu M, Hiles I, Gout I, Fry MJ, Ruiz-Larrea F, Panayotou G, Thompson A, Dhand R, Hsuan J, Totty N et al: Characterization of two 85 kDa proteins that associate with receptor tyrosine kinases, middle-T/pp60c-SRC complexes, and PI3-kinase. Cell 65: 91-104, 1991. (Pubitemid 121001217)
13. Inukai K, Anai M, Van Breda E, Hosaka T, Katagiri H, Funaki M, Fukushima Y, Ogihara T, Yazaki Y, Kikuchi, Oka Y and Asano T: A novel 55-kDa regulatory subunit for phosphatidylinositol 3-kinase structurally similar to p55PIK is generated by alternative splicing of the p85alpha gene. J Biol Chem 271: 5317-5320, 1996.
14. Pons S, Asano T, Glasheen E, Miralpeix M, Zhang Y, Fisher TL, Myers MG Jr., Sun XJ and White MF: The structure and function of p55PIK reveal a new regulatory subunit for phosphatidylinositol 3-kinase. Mol Cell Biol 15: 4453-4465, 1995.
15. Hawkins PT, Jackson TR and Stephens LR: Platelet-derived growth factor stimulates synthesis of PtdIns(3,4,5)P3 by activating a PtdIns(4,5)P2 3-OH kinase. Nature 358: 157-159, 1992.
16. Stephens LR, Hughes KT and Irvine RF: Pathway of phosphatidylinositol(3, 4,5)-trisphosphate synthesis in activated neutrophils. Nature 351: 33-39, 1991. (Pubitemid 21896524)
17. Alessi DR, Deak M, Casamayor A, Caudwell FB, Morrice N, Norman DG, Gaffney P, Reese CB, MacDougall CN, Harbison D, Ashworth A and Bownes M: 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol 7: 776-789, 1997. (Pubitemid 27441832)
18. Le Good JA, Ziegler WH, Parekh DB, Alessi DR, Cohen P and Parker PJ: Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 281: 2042-2045, 1998. (Pubitemid 28475494)
19. Vanhaesebroeck B and Alessi DR: The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 346 Pt 3: 561-576, 2000. (Pubitemid 30171014)
20. MacDougall LK, Domin J and Waterfield MD: A family of phosphoinositide 3-kinases in Drosophila identifies a new mediator of signal transduction. Curr Biol 5: 1404-1415, 1995. (Pubitemid 3008923)
21. Molz L, Chen YW, Hirano M and Williams LT: Cpk is a novel class of Drosophila PtdIns 3-kinase containing a C2 domain. J Biol Chem 271: 13892-13899, 1996. (Pubitemid 26185437)
22. Domin J, Pages F, Volinia S, Rittenhouse SE, Zvelebil MJ, Stein RC and Waterfield MD: Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. Biochem J 326(Pt 1): 139-147, 1997. (Pubitemid 27386928)
23. Arcaro A, Volinia S, Zvelebil MJ, Stein R, Watton SJ, Layton MJ, Gout I, Ahmadi K, Downward J and Waterfield MD: Human phosphoinositide 3-kinase C2beta, the role of calcium and the C2 domain in enzyme activity. J Biol Chem 273: 33082-33090, 1998. (Pubitemid 28557705)
24. Misawa H, Ohtsubo M, Copeland NG, Gilbert DJ, Jenkins NA and Yoshimura A: Cloning and characterization of a novel class II phosphoinositide 3-kinase containing C2 domain. Biochem Biophys Res Commun 244: 531-539, 1998. (Pubitemid 28414116)
25. Ono F, Nakagawa T, Saito S, Owada Y, Sakagami H, Goto K, Suzuki M, Matsuno S and Kondo H: A novel class II phosphoinositide 3-kinase predominantly expressed in the liver and its enhanced expression during liver regeneration. J Biol Chem 273: 7731-7736, 1998. (Pubitemid 28152804)
26. Brown RA, Domin J, Arcaro A, Waterfield MD and Shepherd PR: Insulin activates the alpha isoform of class II phosphoinositide 3-kinase. J Biol Chem 274: 14529-14532, 1999.
27. Arcaro A, Zvelebil MJ, Wallasch C, Ullrich A, Waterfield MD and Domin J: Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors. Mol Cell Biol 20: 3817-3830, 2000. (Pubitemid 30314481)
28. Katso RM, Pardo OE, Palamidessi A, Franz CM, Marinov M, De Laurentiis A, Downward J, Scita G, Ridley AJ, Waterfield MD and Arcaro A: Phosphoinositide 3-kinase C2beta regulates cytoskeletal organization and cell migration via Rac-dependent mechanisms. Mol Biol Cell 17: 3729-3744, 2006. (Pubitemid 44330861)
29. Arcaro A, Khanzada UK, Vanhaesebroeck B, Tetley TD, Waterfield MD and Seckl MJ: Two distinct phosphoinositide 3- kinases mediate polypeptide growth factor-stimulated PKB activation. Embo J 21: 5097-5108, 2002.
30. MacDougall LK, Gagou ME, Leevers SJ, Hafen E and Waterfield MD: Targeted expression of the class II phosphoinositide 3- kinase in Drosophila melanogaster reveals lipid kinase-dependent effects on patterning and interactions with receptor signaling pathways. Mol Cell Biol 24: 796-808, 2004. (Pubitemid 38057930)
31. Maffucci T, Cooke FT, Foster FM, Traer CJ, Fry MJ and Falasca M: Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration. J Cell Biol 169: 789-799, 2005. (Pubitemid 41002884)
32. Domin J, Harper L, Aubyn D, Wheeler M, Florey O, Haskard D, Yuan M and Zicha D: The class II phosphoinositide 3-kinase PI3K-C2beta regulates cell migration by a PtdIns3P-dependent mechanism. J Cell Physiol 205: 452-462, 2005. (Pubitemid 41598860)
33. Liu Z, Sun C, Zhang Y, Ji Z and Yang G: Phosphatidylinositol 3-kinase-C2beta inhibits cisplatin-mediated apoptosis via the AKT pathway in oesophageal squamous cell carcinoma. J Int Med Res 39: 1319-1332, 2011.
34. Russo A and O'Bryan JP: Intersectin 1 is required for neuroblastoma tumorigenesis. Oncogene, 2012.
35. Diouf B, Cheng Q, Krynetskaia NF, Yang W, Cheok M, Pei D, Fan Y, Cheng C, Krynetskiy EY, Geng H, Chen S, Thierfelder WE, Mullighan CG, Downing JR, Hsieh P, Pui CH, Relling MV and Evans WE: Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat Med 17: 1298-1303, 2011.
36. Harada K, Truong AB, Cai T and Khavari PA: The class II phosphoinositide 3-kinase C2beta is not essential for epidermal differentiation. Mol Cell Biol 25: 11122-11130, 2005. (Pubitemid 41747152)
37. Yuan TL and Cantley LC: PI3K pathway alterations in cancer: variations on a theme. Oncogene 27: 5497-5510, 2008.
38. Sansal I and Sellers WR: The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22: 2954-2963, 2004. (Pubitemid 41079915)
39. Courtney KD, Corcoran RB and Engelman JA: The PI3K pathway as drug target in human cancer. J Clin Oncol 28: 1075-1083, 2010.
40. Wong KK, Engelman JA and Cantley LC: Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 20: 87-90, 2010.
41. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B and Velculescu VE: High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554, 2004. (Pubitemid 38541907)
42. Weir B, Zhao X and Meyerson M: Somatic alterations in the human cancer genome. Cancer Cell 6: 433-438, 2004. (Pubitemid 39469978)
43. Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, McLendon RE, Fults DW, Velculescu VE, Bigner DD and Yan H: Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 64: 5048-5050, 2004. (Pubitemid 39006515)
44. Arcaro A and Guerreiro AS: The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genomics 8: 271-306, 2007. (Pubitemid 351210980)
45. Hayakawa M, Kaizawa H, Kawaguchi K, Ishikawa N, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, Waterfield MD, Parker P and Workman P: Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem 15: 403-412, 2007. (Pubitemid 44738565)
46. Hayakawa M, Kaizawa H, Moritomo H, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, Workman P, Waterfield MD and Parker P: Synthesis and biological evaluation of pyrido[3′,2′:4,5]furo[3,2-d] pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem Lett 17: 2438-2442, 2007. (Pubitemid 46507793)
47. Hayakawa M, Kaizawa H, Moritomo H, Koizumi T, Ohishi T, Okada M, Ohta M, Tsukamoto S, Parker P, Workman P and Waterfield M: Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem 14: 6847-6858, 2006. (Pubitemid 44307656)
48. Hayakawa M, Kawaguchi K, Kaizawa H, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, Parker P, Workman P and Waterfield MD: Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem 15: 5837-5844, 2007. (Pubitemid 47043472)
49. Guerreiro AS, Fattet S, Fischer B, Shalaby T, Jackson SP, Schoenwaelder SM, Grotzer MA, Delattre O and Arcaro A: Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration. Clin Cancer Res 14: 6761-6769, 2008.
50. Guerreiro AS, Fattet S, Kulesza DW, Atamer A, Elsing AN, Shalaby T, Jackson SP, Schoenwaelder SM, Grotzer MA, Delattre O and Arcaro A: A sensitized RNA interference screen identifies a novel role for the PI3K p110gamma isoform in medulloblastoma cell proliferation and chemoresistance. Mol Cancer Res 9: 925-935, 2011.
51. Doepfner KT, Spertini O and Arcaro A: Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/AKT pathway. Leukemia 21: 1921-1930, 2007. (Pubitemid 47299965)
52. Pardo OE, Arcaro A, Salerno G, Tetley TD, Valovka T, Gout I and Seckl MJ: Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells. Oncogene 20: 7658-7667, 2001. (Pubitemid 33111865)
53. Maschler S, Wirl G, Spring H, Bredow DV, Sordat I, Beug H and Reichmann E: Tumor cell invasiveness correlates with changes in integrin expression and localization. Oncogene 24: 2032-2041, 2005. (Pubitemid 40516196)
54. Boller D, Schramm A, Doepfner KT, Shalaby T, von Bueren AO, Eggert A, Grotzer MA and Arcaro A: Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells. Clin Cancer Res 14: 1172-1181, 2008. (Pubitemid 351302566)
55. Hirt A, Schmid AM, Ammann RA and Leibundgut K: In pediatric lymphoblastic leukemia of B-cell origin, a small population of primitive blast cells is noncycling, suggesting them to be leukemia stem cell candidates. Pediatr Res 69: 194-199, 2011.
56. Fattet S, Haberler C, Legoix P, Varlet P, Lellouch-Tubiana A, Lair S, Manie E, Raquin MA, Bours D, Carpentier S, Barillot E, Grill J, Doz F, Puget S, Janoueix-Lerosey I and Delattre O: Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol 218: 86- 94, 2009.
57. Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R and Mathieu C: An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 25: 386-401, 2001. (Pubitemid 34164011)
58. Guerreiro AS, Boller D, Shalaby T, Grotzer MA and Arcaro A: Protein kinase B modulates the sensitivity of human neuroblastoma cells to insulin-like growth factor receptor inhibition. Int J Cancer 119: 2527-2538, 2006. (Pubitemid 44691305)
59. De Laurentiis A, Pardo OE, Palamidessi A, Jackson SP, Schoenwaelder SM, Reichmann E, Scita G and Arcaro A: The catalytic class I(A) PI3K isoforms play divergent roles in breast cancer cell migration. Cell Signal 23: 529-541, 2011.
60. Knobbe CB and Reifenberger G: Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol- 3′-kinase/protein kinase B (AKT) signal transduction pathway in glioblastomas. Brain Pathol 13: 507-518, 2003. (Pubitemid 37420695)
61. Nobusawa S, Lachuer J, Wierinckx A, Kim YH, Huang J, Legras C, Kleihues P and Ohgaki H: Intratumoral patterns of genomic imbalance in glioblastomas. Brain Pathol 20: 936-944, 2010.
62. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, Lowenberg B and Delwel R: Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350: 1617-1628, 2004.
63. Liu P, Cheng H, Roberts TM and Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8: 627-644, 2009.
64. Zhao JJ, Cheng H, Jia S, Wang L, Gjoerup OV, Mikami A and Roberts TM: The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci USA 103: 16296-16300, 2006. (Pubitemid 44715190)
65. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM and Zhao JJ: Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454: 776-779, 2008.
66. Sujobert P, Bardet V, Cornillet-Lefebvre P, Hayflick JS, Prie N, Verdier F, Vanhaesebroeck B, Muller O, Pesce F, Ifrah N, Hunault-Berger M, Berthou C, Villemagne B, Jourdan E, Audhuy B, Solary E, Witz B, Harousseau JL, Himberlin C, Lamy T, Lioure B, Cahn JY, Dreyfus F, Mayeux P, Lacombe C and Bouscary D: Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106: 1063-1066, 2005. (Pubitemid 41076455)
67. Billottet C, Banerjee L, Vanhaesebroeck B and Khwaja A: Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting ATRA-induced differentiation. Cancer Res 69: 1027-1036, 2009.
68. Meadows SA, Vega F, Kashishian A, Johnson D, Diehl V, Miller LL, Younes A and Lannutti BJ: PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 119: 1897-1900, 2012.
69. Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, Druker BJ, Puri KD, Ulrich RG and Giese NA: CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117: 591-594, 2011.
70. Elis W, Triantafellow E, Wolters NM, Sian KR, Caponigro G, Borawski J, Gaither LA, Murphy LO, Finan PM and Mackeigan JP: Down-regulation of class II phosphoinositide 3-kinase alpha expression below a critical threshold induces apoptotic cell death. Mol Cancer Res 6: 614-623, 2008. (Pubitemid 351521843)
71. Koutros S, Schumacher FR, Hayes RB, Ma J, Huang WY, Albanes D, Canzian F, Chanock SJ, Crawford ED, Diver WR, Feigelson HS, Giovanucci E, Haiman CA, Henderson BE, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Le Marchand L, Riboli E, Siddiq A, Stampfer MJ, Stram DO, Thomas G, Travis RC, Thun MJ, Yeager M and Berndt SI: Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer. Cancer Res 70: 2389-2396, 2010.